Table 1.
Major latency reversing agent (LRA) categories and their representatives
| Categories | Representative Agents |
Clinical trial number* | Reference |
|---|---|---|---|
| HDAC inhibitor | Vorinostat (SAHA) |
NCT01365065; NCT03198559; NCT02707900; NCT01319383; NCT03212989; NCT02475915; NCT02336074 |
[102, 104–107] |
| Panobinostat | NCT01680094; NCT02471430 | [108] | |
| valproic acid (VPA) |
NCT00312546; NCT00614458; NCT00000629; NCT00289952 |
[109, 110] | |
| romidepsin |
NCT02616874; NCT02092116; NCT01933594; NCT03041012; NCT02850016 |
[111–113] | |
| chidamide | NCT02513901; NCT02902185 | [114] | |
| sodium butyrate | Not tested | [115] | |
| HMT inhibitor | BIX01294 | Not tested | [116] |
| Chaetocin | Not tested | [39] | |
| PKC agonist | prostratin | Not tested | [117, 118] |
| bryostatin-1 | NCT02269605 | [119, 120] | |
| ingenol derivatives |
Not tested | [99, 121, 122] |
|
| P-TEFb activator | hexamethylene bisacetamide |
Not tested | [123] |
| JQ1 | Not tested | [100] | |
| DNA methyltransferase inhibitors |
decitabine and its analog azacytidine |
Not tested | [124] |
| unclassified | disulfiram |
NCT00878306; NCT01944371; NCT03198559; NCT01286259; NCT00002065 |
[125–127] |
*
source: clinicaltrials.gov
HDAC, histone deacetylase; HMT, histone methyltransferase; PKC, protein kinase C; P-TEFb, positive transcription elongation factor b.